CUE Cue Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CUE

Price (delayed)

$32.12

Market cap

$129.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.98

Enterprise value

$116.22M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 39

Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the ...

Highlights
The EPS has soared by 74% YoY and by 41% QoQ
The net income has soared by 52% YoY and by 27% from the previous quarter
The company's equity fell by 18% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cuebiopharma.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CUE

CUE stock price

How has the Cue Biopharma stock price performed over time
Intraday
-2.93%
1 week
3.08%
1 month
23.49%
1 year
18.31%
YTD
250.66%
QTD
1.77%

Financial performance

How have Cue Biopharma's revenue and profit performed over time
Revenue
$32.73M
Gross profit
$32.73M
Operating income
-$19.62M
Net income
-$19.52M
Gross margin
100%
Net margin
-59.6%
Cue Biopharma's operating margin has soared by 88% YoY and by 38% from the previous quarter
CUE's net margin has surged by 88% year-on-year and by 38% since the previous quarter
The company's operating income has surged by 52% YoY and by 26% QoQ
The net income has soared by 52% YoY and by 27% from the previous quarter

Price vs fundamentals

How does CUE's price correlate with its fundamentals

Growth

What is Cue Biopharma's growth rate over time

Valuation

What is Cue Biopharma stock price valuation
P/E
N/A
P/B
4.84
P/S
4.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.55
The EPS has soared by 74% YoY and by 41% QoQ
The P/B is 120% above the last 4 quarters average of 2.2 and 51% above the 5-year quarterly average of 3.2
The company's equity fell by 18% QoQ
The price to sales (P/S) is 88% lower than the 5-year quarterly average of 40.3 and 6% lower than the last 4 quarters average of 5.0
CUE's revenue is up by 19% since the previous quarter

Efficiency

How efficient is Cue Biopharma business performance
The ROS has soared by 88% YoY and by 39% QoQ
The ROIC has soared by 80% YoY and by 61% QoQ
Cue Biopharma's return on equity has surged by 57% YoY and by 40% QoQ
The ROA has soared by 53% YoY and by 31% from the previous quarter

Dividends

What is CUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CUE.

Financial health

How did Cue Biopharma financials performed over time
Cue Biopharma's total liabilities has decreased by 41% from the previous quarter and by 41% YoY
The total assets is up by 39% year-on-year but it has declined by 27% since the previous quarter
CUE's debt is 84% smaller than its equity
CUE's debt to equity has shrunk by 85% YoY
CUE's debt has dropped by 52% year-on-year and by 18% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.